Clinical investigations of Toll-like receptor agonists.
Standard
Clinical investigations of Toll-like receptor agonists. / Meyer, Thomas; Stockfleth, Eggert.
in: EXPERT OPIN INV DRUG, Jahrgang 17, Nr. 7, 7, 2008, S. 1051-1065.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Clinical investigations of Toll-like receptor agonists.
AU - Meyer, Thomas
AU - Stockfleth, Eggert
PY - 2008
Y1 - 2008
N2 - BACKGROUND: Toll-like receptors (TLR) represent a family of surface molecules that function as primary sensors of the innate immune system to recognize microbial pathogens. Ligand binding to TLR results in activation of cellular signaling pathways that regulate expression of genes involved in inflammation and immunity. OBJECTIVE: Use of synthetic TLR ligands (agonists) for treatment and prevention of infectious and neoplastic diseases. METHODS: Review of literature about clinical investigations of agonists of TLR 4, 7, 8, and 9. RESULTS/CONCLUSIONS: Imiquimod was the first TLR agonist approved for treatment of anogenital warts, actinic keratosis and superficial basal cell carcinoma in humans. Several other agonists of TLRs 4, 7, 8 and 9 were also shown to be effective for treatment of infections and cancers and, furthermore, were used as adjuvants for vaccination. Based on safety and efficacy of the TLR agonists used to date, applications are likely to increase in the future.
AB - BACKGROUND: Toll-like receptors (TLR) represent a family of surface molecules that function as primary sensors of the innate immune system to recognize microbial pathogens. Ligand binding to TLR results in activation of cellular signaling pathways that regulate expression of genes involved in inflammation and immunity. OBJECTIVE: Use of synthetic TLR ligands (agonists) for treatment and prevention of infectious and neoplastic diseases. METHODS: Review of literature about clinical investigations of agonists of TLR 4, 7, 8, and 9. RESULTS/CONCLUSIONS: Imiquimod was the first TLR agonist approved for treatment of anogenital warts, actinic keratosis and superficial basal cell carcinoma in humans. Several other agonists of TLRs 4, 7, 8 and 9 were also shown to be effective for treatment of infections and cancers and, furthermore, were used as adjuvants for vaccination. Based on safety and efficacy of the TLR agonists used to date, applications are likely to increase in the future.
M3 - SCORING: Zeitschriftenaufsatz
VL - 17
SP - 1051
EP - 1065
JO - EXPERT OPIN INV DRUG
JF - EXPERT OPIN INV DRUG
SN - 1354-3784
IS - 7
M1 - 7
ER -
